title: [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
abstract: This case report shows how denosumab apparently treated bisphosphonate-refractory hypercalcaemia caused by a neuroendocrine tumour of the pancreas in a 48-year-old woman. We cannot eliminate the possibility that the patient's DOTATOC-treatment contributed to the decline in plasma calcium concentration. Preliminary results from a recent large, clinical trial, suggest that denosumab is a more potent treatment of malignancy-associated hypercalcaemia than bisphosphonates.
authors.affiliation: Klinisk Farmakologisk Afdeling, Bispebjerg -Hospital, Bispebjerg Bakke 23, 2400 København NV. E-mail: louisestoerling@gmail.com.
authors.forename: Louise
authors.initials: L
authors.lastname: Størling
authors.forename: Gerda Elisabeth
authors.initials: GE
authors.lastname: Villadsen
authors.forename: Klaus
authors.initials: K
authors.lastname: Krogh
authors.forename: Peter
authors.initials: P
authors.lastname: Vestergaard
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood*; D000069448:Denosumab / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000150:complications / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000150:complications / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D000069448:Denosumab; D002118:Calcium